Cited 0 times in
The novel use and feasibility of hemostatic oxidized regenerated cellulose agent (SurgiGuard®): multicenter retrospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 노승윤 | - |
dc.date.accessioned | 2024-01-03T00:44:41Z | - |
dc.date.available | 2024-01-03T00:44:41Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 2227-684X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197358 | - |
dc.description.abstract | Background: SurgiGuard® is an absorbent hemostatic agent based on oxidized regenerated cellulose. The efficacy, effects and safety of SurgiGuard® are equivalent to existing hemostatic agents in animal experiments. This study was designed to confirm that the use of SurgiGuard® alone is effective, safe and feasible compared to combination with other hemostatic methods. Methods: We retrospectively reviewed clinical data from 12 surgery departments in seven tertiary centers in South Korea nationwide. All surgeries were performed between January and December 2018. Results: A total of 807 patients were enrolled; 447 patients (55.4%) had comorbidities. The rate of major surgery (operative time ≥4 hours) was 44% (n=355 patients). Regarding the type of SurgiGuard® used in surgery, more than 70% of minor surgeries used non-woven types. In major surgery, more than five SurgiGuards® were used in 7.3% (26 patients), and the proportion of co-usage (with four other hemostatic products) was 19.7% (70 patients). The effectiveness score was higher when SurgiGuard® was used alone in both major (5.3±0.5 vs. 5.1±0.6, P=0.048) and minor surgery (5.4±0.6 vs. 5.2±0.4, P<0.001). Seven patients had immediate re-bleeding, and all of them used SurgiGuard® and other products together. Nine patients reported adverse effects, such as abscess, bleeding, or leg swelling, but we found no direct correlation with SurgiGuard®. Conclusions: SurgiGuard® exhibited greater effectiveness when used alone. No direct adverse effects associated with SurgiGuard® use were reported, and SurgiGuard® had stable feasibility. Prospective comparative studies are needed in the future. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | AME Publishing Company | - |
dc.relation.isPartOf | GLAND SURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | The novel use and feasibility of hemostatic oxidized regenerated cellulose agent (SurgiGuard®): multicenter retrospective study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Seoung Yoon Rho | - |
dc.contributor.googleauthor | Miryung Jin | - |
dc.contributor.googleauthor | Hyun Koo Kim | - |
dc.contributor.googleauthor | Jeong-Ik Park | - |
dc.contributor.googleauthor | Jong-Hwa Park | - |
dc.contributor.googleauthor | Sangchul Yun | - |
dc.contributor.googleauthor | Maria Lee | - |
dc.contributor.googleauthor | Sae Byeol Choi | - |
dc.contributor.googleauthor | Jae-Young Hong | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.identifier.doi | 10.21037/gs-22-675 | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A05469 | - |
dc.relation.journalcode | J00946 | - |
dc.identifier.eissn | 2227-8575 | - |
dc.identifier.pmid | 37727334 | - |
dc.subject.keyword | SurgiGuard® | - |
dc.subject.keyword | hemostasis | - |
dc.subject.keyword | hemostatic agent | - |
dc.subject.keyword | oxidized regenerated cellulose (ORC) | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.contributor.affiliatedAuthor | 노승윤 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 905 | - |
dc.citation.endPage | 916 | - |
dc.identifier.bibliographicCitation | GLAND SURGERY, Vol.12(7) : 905-916, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.